Funding for this research was provided by:
University of Calgary Katthy Taylor Chair in Vascular Dementia (Not applicable)
Article History
Received: 18 July 2019
Revised: 8 September 2019
Accepted: 9 September 2019
First Online: 5 November 2019
Compliance with ethical standards
:
: Dr. Smith reports funding from the Canadian Institutes of Health Research and Brain Canada for studies of biomarkers of cerebral small vessel disease, and consulting fees from Portola Pharmaceuticals and Alnylam Pharmaceuticals for activities outside the submitted work. The other authors report no relevant financial conflicts of interest.
: Approval by an Institutional Review Board was not needed because this was a systematic review based on published work, with no interactions with study participants.